|
|
||||||||
From the Department of Ophthalmology, Toyama Medical and Pharmaceutical University, Toyama, Japan.
| Abstract |
|---|
|
|
|---|
METHODS. Transcorneal diffusion of PGE2 (25 µg/mL or 7.09 x 10-2 mM) with the use of a glass cylinder was achieved to produce aqueous flare elevation in pigmented rabbits. An antiglaucoma agent was topically administered before application of PGE2. Aqueous flare was measured with a laser flare cell meter.
RESULTS. A single instillation of apraclonidine 1.15%, two instillations of epinephrine 1.25%, two instillations of dipivefrin 0.1%, and two instillations and one instillation of dipivefrin 0.04% eye drops inhibited 98%, 96%, 87%, 73%, and 47% of PGE2-induced aqueous flare elevation, respectively. Timolol 0.5%, nipradilol 0.25%, dorzolamide 1%, and pilocarpine 2% eye drops had no effects on the increase of PGE2-induced flare.
CONCLUSIONS. Apraclonidine, epinephrine, and dipivefrin eye drops inhibit PGE2-induced elevation of aqueous flare in pigmented rabbits.
| Introduction |
|---|
|
|
|---|
Aqueous flare elevation decreased after repeated applications of PGE2 within a short time (hourly or daily). However, weekly applications of PGE2 did not change the aqueous flare reaction in pigmented rabbits.2 We have also reported that a single instillation (30 minutes before PGE2) of 0.25% clonidine and two instillations (60 and 30 minutes before PGE2) of 0.5% betaxolol inhibits 89% and 32% of PGE2-induced aqueous flare elevation, respectively.3 4 In the present study, we evaluated the effect of topical instillation of antiglaucoma agents on aqueous flare elevation induced by PGE2 in pigmented rabbits.
| Materials and Methods |
|---|
|
|
|---|
Chemicals
Dipivefrin hydrochloride (Pivalephrine, a ß2-agonist) and pilocarpine (Sanpilo, a cholinergic agent) ophthalmic solutions were obtained from Santen Pharmaceutical Company (Osaka, Japan). Timolol maleate (Timoptol, a ß-antagonist) and dorzolamide (Trusopt, a carbonic anhydrase inhibitor) were from Banyu Pharmaceutical Company (Tokyo, Japan). Apraclonidine (Iopidine, an
2-agonist), epinephrine (Epista, a ß2-agonist), and nipradilol (Nipranol, a ß-antagonist with an
1-antagonist) ophthalmic solutions were purchased from Alcon Laboratories (Fort Worth, TX), Senju (Osaka, Japan), and Teika (Toyama, Japan) pharmaceutical companies, respectively.
PGE2 was obtained from Funakoshi Chemicals (Tokyo, Japan). PGE2 was dissolved in 100% ethanol and stored at -70°C. PGE2 solution was diluted to 5% ethanol with 0.9% NaCl just before use. Epinephrine ophthalmic solution was diluted with 0.9% NaCl.
Topical Instillation of Antiglaucoma Agent or Placebo
In one eye, 50 µL 0.1% antiglaucoma agent or placebo (0.9% NaCl) was topically instilled. Instillation took place twice (60 and 30 minutes before PGE2). We also performed single instillations to examine dose and time dependency. The bottles were masked, and the person who administered the eye drops had no preliminary knowledge of the contents.
Transcorneal Diffusion of PGE2
For transcorneal diffusion, a glass cylinder (11 mm in diameter) was attached to the cornea, as described by Hirata et al.1
Next, 600 µL of PGE2 solution (25 µg/mL or 7.09 x 10-2 mM) was delivered into the cylinder and pipetted out 4 minutes later. The cylinder was removed, and the corneal surface and conjunctival sac were rinsed with 20 mL 0.9% NaCl. The eyes received a second transcorneal application of PGE2, 1 or 2 weeks later (Fig. 1)
. PGE2-induced flare elevation was measured in the eye pretreated with antiglaucoma agent or placebo (0.9% NaCl) and again after the second PGE2 application.
|
Aqueous flare elevation was expressed as the area under the curve (AUC) for each eye. Inhibition was estimated from the AUCs in the same eye by the following equation: inhibition (%) = 1 - [(AUC with treatment)/(AUC without treatment)] x100. The measurer had no preliminary knowledge of the treatment.
Statistics
Statistical analysis was performed using the Dunn multiple comparisons procedure. P < 0.05 was considered significant.
| Results |
|---|
|
|
|---|
No marked changes in the systemic condition, including body weight and behavior, were noted after the transcorneal diffusion of PGE2 (7.09 x 10-2 mM).
After PGE2 was administered, aqueous flare increased, reached its maximum (470 ± 37 photon counts/ms) at 60 to 90 minutes, and then gradually decreased and returned to baseline level after 7 to 8 hours (Fig. 2) . When apraclonidine 1.15% was topically instilled 60 minutes before PGE2, aqueous flare did not increase. Single instillation of apraclonidine 1.15%, two instillations of epinephrine 1.25%, two instillations of dipivefrin 0.1%, and two and one instillations of dipivefrin 0.04% eye drops inhibited 98%, 96%, 87%, 73%, and 47% of PGE2-induced increase in aqueous flare, respectively (Table 1) .
|
|
|
| Discussion |
|---|
|
|
|---|
Several researchers have reported a relationship between epinephrine and aqueous humor: Townsend and Brubaker8 postulated that epinephrine increases the rate of the uveoscleral outflow pathway in humans. Camras et al.9 reported on the inhibition of epinephrine-induced reduction of intraocular pressure by systemic indomethacin in humans. Miyake et al.10 11 reported that epinephrine induces disruption of the blood-aqueous barrier several months after drug administration in rabbits and humans. Anderson and Wilson12 described inhibition by indomethacin of the increased facility of outflow induced by adrenaline in rabbits. Mori et al.13 reported that a single instillation of epinephrine affects neither the protein concentration in the anterior chamber nor the aqueous flow rate in humans. In our present study, topical instillation of epinephrine and dipivefrin (dipivalyl epinephrine) inhibited the PGE2-induced elevation of aqueous flare in rabbits. Miyake et al.14 further reported synthesis of PGE2 in rabbit eyes with topically applied epinephrine.
However, our results showed that a single instillation of 1.25% epinephrine 30 minutes before PGE2 inhibited 90% of the increase in PGE2-induced flare. The difference between our results and the findings reported by Miyake et al.10 14 may be due to the varied instillation times. Okada and Shimada15 reported that intravenous epinephrine and intramuscular steroid inhibit the increase of permeability of the bloodaqueous barrier induced by reverse passive Arthus reactions in rabbits. Our results were similar to those described by Okada and Shimada.15 The iris in our animals became slightly pale after topical instillation of 1.25% epinephrine. Vasoconstriction induced by epinephrine may play a role in inhibition of the PGE2-induced elevation in aqueous flare. Topical epinephrine or dipivefrin effects on the elevation of aqueous flare after argon laser iridotomy should be examined in humans.
We have reported that betaxolol inhibits the PGE2-induced elevation in aqueous flare in rabbits and suggest that the calcium-channel blocking activity of betaxolol may be involved in the inhibition.4 Miichi and Nagataki16 reported that timolol does not alter the function of the bloodaqueous barrier in the cynomolgus monkey. Kanno et al.17 reported that a single instillation of nipradilol shows no significant effect on bloodaqueous barrier permeability in rabbits.
In our present study, timolol and nipradilol did not inhibit elevation of aqueous flare. It is unlikely that the ß-blocking activity of the drugs is involved in the inhibition of the elevation of flare in rabbits. Mori and Araie18 reported that timolol induces elevation of protein concentration in humans. The discrepancy between our results and the findings reported by Mori and Araie18 may be due to the difference in species.19
In the present study, topical dorzolamide and pilocarpine did not alter the PGE2-induced elevation of aqueous flare. Miichi and Nagataki16 reported that the bloodaqueous barrier was not altered by pilocarpine in the cynomolgus monkey. Our findings support this.16
PGE2-like activity was detected in the aqueous humor after paracentesis in rabbits,20 and it may be involved in traumatic iridocyclitis in rabbits. The bloodaqueous barrier in rabbits has a unique sensitivity to PGs.19 Therefore, the findings in the present study are not representative of the effects seen in humans. The mechanisms of inhibition by epinephrine and dipivefrin of the PGE2-induced elevation of aqueous flare in rabbits should be investigated.
| Footnotes |
|---|
Commercial relationships policy: N.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Yoriko Hayasaka, Department of Ophthalmology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan; ophthal{at}ms.toyama-mpu.ac.jp
| References |
|---|
|
|
|---|
-blocking and nitroglycerin-like activities, on aqueous humor dynamics and fundus circulation Invest Ophthalmol Vis Sci 39,736-743This article has been cited by other articles:
![]() |
Y. Hayasaka, S. Hayasaka, X.-Y. Zhang, and Y. Nagaki Effects of Topical Anti-inflammatory and Antiallergic Eyedrops on Prostaglandin E2-Induced Aqueous Flare Elevation in Pigmented Rabbits Arch Ophthalmol, July 1, 2002; 120(7): 950 - 953. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |